These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30924488)

  • 1. 2-Azo-, 2-diazocine-thiazols and 2-azo-imidazoles as photoswitchable kinase inhibitors: limitations and pitfalls of the photoswitchable inhibitor approach.
    Schehr M; Ianes C; Weisner J; Heintze L; Müller MP; Pichlo C; Charl J; Brunstein E; Ewert J; Lehr M; Baumann U; Rauh D; Knippschild U; Peifer C; Herges R
    Photochem Photobiol Sci; 2019 Jun; 18(6):1398-1407. PubMed ID: 30924488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.
    Peifer C; Abadleh M; Bischof J; Hauser D; Schattel V; Hirner H; Knippschild U; Laufer S
    J Med Chem; 2009 Dec; 52(23):7618-30. PubMed ID: 19591487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of 4-fluorophenyl-imidazole p38α MAPK, CK1δ and JAK2 kinase inhibitors.
    Seerden JP; Leusink-Ionescu G; Woudenberg-Vrenken T; Dros B; Molema G; Kamps JA; Kellogg RM
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3412-8. PubMed ID: 24930833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK.
    Halekotte J; Witt L; Ianes C; Krüger M; Bührmann M; Rauh D; Pichlo C; Brunstein E; Luxenburger A; Baumann U; Knippschild U; Bischof J; Peifer C
    Molecules; 2017 Mar; 22(4):. PubMed ID: 28338621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors.
    Schulte AM; Kolarski D; Sundaram V; Srivastava A; Tama F; Feringa BL; Szymanski W
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
    Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
    Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
    Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
    Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An optimized and versatile synthesis to pyridinylimidazole-type p38α mitogen activated protein kinase inhibitors.
    El-Gokha A; Laufer SA; Koch P
    Org Biomol Chem; 2015 Nov; 13(43):10699-704. PubMed ID: 26351018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
    Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of triazolopyridazinones as potent p38α inhibitors.
    Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
    Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
    Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological testing of N-aminoimidazole-based p38alpha MAP kinase inhibitors.
    Bracht C; Hauser DR; Schattel V; Albrecht W; Laufer SA
    ChemMedChem; 2010 Jul; 5(7):1134-42. PubMed ID: 20473979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase.
    Munoz L; Selig R; Yeung YT; Peifer C; Hauser D; Laufer S
    Anal Biochem; 2010 Jun; 401(1):125-33. PubMed ID: 20175985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.
    Astolfi A; Kudolo M; Brea J; Manni G; Manfroni G; Palazzotti D; Sabatini S; Cecchetti F; Felicetti T; Cannalire R; Massari S; Tabarrini O; Loza MI; Fallarino F; Cecchetti V; Laufer SA; Barreca ML
    Eur J Med Chem; 2019 Nov; 182():111624. PubMed ID: 31445234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
    Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
    J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore design of p38α MAP kinase inhibitors with either 2,4,5-trisubstituted or 1,2,4,5-tetrasubstituted imidazole scaffold.
    Scior T; Domeyer DM; Cuanalo-Contreras K; Laufer SA
    Curr Med Chem; 2011; 18(10):1526-39. PubMed ID: 21428890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(1H-Pyrazol-3-yl)quinazolin-4-amines as a novel class of casein kinase 1δ/ε inhibitors: Synthesis, biological evaluation and molecular modeling studies.
    Karthikeyan C; Jharia P; Waiker DK; Nusbaum AC; Amawi H; Kirwen EM; Christman R; Arudra SKC; Meijer L; Tiwari AK; Trivedi P
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2663-2667. PubMed ID: 28487075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib.
    Heintze L; Schmidt D; Rodat T; Witt L; Ewert J; Kriegs M; Herges R; Peifer C
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinase and GPCR polypharmacological approach for the identification of efficient anticancer medicines.
    Park H; Jung HY; Mah S; Kim K; Hong S
    Org Biomol Chem; 2020 Oct; 18(41):8402-8413. PubMed ID: 33112339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for the interaction between casein kinase 1 delta and a potent and selective inhibitor.
    Long A; Zhao H; Huang X
    J Med Chem; 2012 Jan; 55(2):956-60. PubMed ID: 22168824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.